DENGUE VACCINE DEVELOPMENT

Award Information
Agency:
Department of Defense
Amount:
$553,000.00
Program:
SBIR
Contract:
N/A
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
Army
Award Year:
1988
Phase:
Phase II
Agency Tracking Number:
3977
Solicitation Topic Code:
N/A
Small Business Information
Hawaii Biotechnology Group Inc
99-193 Aiea Heights Dr, Aiea, HI, 96701
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 Morton Mandel
 (808) 487-5565
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE ULTIMATE OBJECTIVE OF THIS PROJECT IS THE PRODUCTION OF A DENGUE VACCINE. THE FOUR DENGUE VIRUSES (SEROTYPES) AS A GROUP ARE BY FAR THE MOST IMPORTANT VIRUSES TRANSMITTED TO MAN BY ARTHROPODS AND IN TERMS OF GLOBAL MORBIDITY ARE RESPONSIBLE FOR SEVERAL HUNDRED THOUSAND TO SEVERAL MILLION CASES ANNUALLY. IN PHASE I RANDOM FRAGMENTS OF THE DENGUE VIRUS 2 (RNA) GENOME WILL BE CLONED INTO A BACTERIAL EXPRESSION VECTOR. THESE RANDOMLY GENERATED FRAGMENTS WILL BE PRODUCED IN TWO WAYS TO ENSURE COMPLETE COVERAGE OF THE RNA GENOME.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government